|
Immatics
immatics is a biopharmaceutical company dedicated to the development of innovative cancer immunotherapeutics.
immatics' proprietary technology for the identification of tumor-associated pep-tides (TUMAPs) enables the development of novel anti-cancer vaccines for multiple cancer indications. immatics is currently developing two multi-TUMAP products in clinical phase II studies - IMA901 for the treatment of renal cell carcinoma (RCC) and IMA910 for the treatment of colorectal carcinoma (CRC). A third product, IMA950, for the treatment of malignant glioma (braincancer) is expected to enter development in early 2010. Further product candidates are currently in pre-clinical development. immatics was founded in 2000 as a spin-off from the Institute of Immunology at the University of Tuebingen (Prof. Hans-Georg Rammensee) and is based in Tuebingen and in Munich, both in Germany.
For further information please visit: www.immatics.com. |
